Aardvark Therapeutics (AARD) vs OnKure Therapeutics (OKUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
OnKure Therapeutics (OKUR) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 16.3% versus a loss of 69.6%. OnKure Therapeutics is the larger company by market cap ($98.0 million vs $97.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | OKUR |
|---|---|---|
| Share price | $4.45 | $2.42 |
| Market cap | $97.39M | $98.00M |
| 1-day change | -6.51% | +0.41% |
| YTD return | -66.10% | -16.90% |
| 1-year return | -69.58% | -16.32% |
| 5-year return | — | -96.26% |
| EPS (TTM) | $-3.21 | $-3.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.60 | $5.38 |
| 52-week low | $3.35 | $2.13 |
| Distance from 52-week high | -73.19% | -55.02% |
| Analyst consensus | buy | none |
| Avg. price target upside | +149.66% | +540.50% |
| Average volume | 146.39K | 223.45K |
| Shares outstanding | 21.88M | 40.50M |
| Employees | 28 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKUR has outperformed AARD by 53.3 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees
AARD vs OKUR FAQ
Which is bigger, Aardvark Therapeutics or OnKure Therapeutics?
OnKure Therapeutics (OKUR) is larger, with a market capitalization of $98.00M compared with $97.39M for Aardvark Therapeutics (AARD).
Which stock has performed better over the past year, AARD or OKUR?
OKUR returned -16.32% over the past 12 months, compared with -69.58% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and OnKure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.